Bellicum Pharmaceuticals (NASDAQ:BLCM) Earns Sell Rating from Analysts at initiated coverage on shares of Bellicum Pharmaceuticals (NASDAQ:BLCM – Free Report) in a research report report published on Monday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Bellicum Pharmaceuticals Stock Down 14.9 % Shares of BLCM stock opened at $0.15 on Monday. The firm’s 50 day moving average price is […]

Leave a Reply

Your email address will not be published.

Previous post Natuzzi (NYSE:NTZ) Earns Hold Rating from Analysts at
Next post Israel demolishing Gaza’s economy – UN